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Implementation of a Large System-Wide Hepatitis C Virus 
Screening and Linkage to Care Program for Baby Boomers
Mariana Castrejón,1 Kara W. Chew,1 Marjan Javanbakht,4 Romney Humphries,2 Sammy Saab,3 and Jeffrey D. Klausner1,4
1Department of Medicine, Division of Infectious Diseases, 2Department of Pathology and Laboratory Medicine, and 3Department of Medicine, Division of Digestive Diseases, David Geffen School 
of Medicine, University of California, Los Angeles; and 4Department of Epidemiology, University of California, Los Angeles Fielding School of Public Health
Background. We implemented and evaluated a large health system-wide hepatitis C virus (HCV) screening and linkage to care 
program for persons born between 1945 and 1965 (“baby boomers”).
Methods. An electronic health record (EHR) clinical decision support (CDS) tool for HCV screening for baby boomers was 
introduced in August 2015 for patients seen in the outpatient University of California, Los Angeles healthcare system setting. An 
HCV care coordinator was introduced in January 2016 to facilitate linkage to HCV care. We compared HCV testing in the year prior 
(August 2014–July 2015) to the year after (August 2015–July 2016) implementation of the CDS tool. Among patients with reactive 
HCV antibody testing, we compared outcomes related to the care cascade including HCV ribonucleic acid (RNA) testing, HCV RNA 
positivity, and linkage to HCV specialty care.
Results. During the study period, 19 606 participants were screened for HCV antibody. Hepatitis C virus antibody screening 
increased 145% (from 5676 patients tested to 13 930 tested) after introduction of the CDS intervention. Screening increased across 
all demographic groups including age, sex, and race/ethnicity, with the greatest increases among those in the older age groups. The 
addition of an HCV care coordinator increased follow-up HCV RNA testing for HCV antibody positive patients from 83% to 95%. 
Ninety-four percent of HCV RNA positive patients were linked to care postimplementation.
Conclusions. Introduction of an EHR CDS tool and care coordination markedly increased the number of baby boomers 
screened for HCV, rates of follow-up HCV RNA testing, and linkage to specialty HCV care for patients with chronic HCV infection.
Keywords. baby boomers; care cascade; hepatitis C virus; linkage to care; screening.
 
The US Centers for Disease Control and Prevention and US 
Preventive Services Task Force (USPSTF) recommend a one-time 
hepatitis C virus (HCV) screening for adults born between 1945 and 
1965 (a birth cohort known as “baby boomers”) [1, 2]. Approximately 
three-quarters of persons chronically infected with HCV are baby 
boomers, many of whom are unaware of their infection [2, 3].
Efforts to increase case identification and increase linkage to 
care and treatment have had mixed results [4, 5]. The biggest 
gaps are in screening and linkage to care [5]. It is essential that 
those particular areas are optimized, to increase downstream 
treatment rates and improve HCV-related patient outcomes, 
reduce future healthcare costs, and limit HCV transmission [6].
We implemented an HCV screening and linkage to care initi-
ative within the University of California, Los Angeles (UCLA) 
Health, a large complex health system with a broad catchment area, 
following recommendations from the USPSTF for one-time HCV 
screening in persons born between 1945 and 1965 [1]. Our aim in 
this analysis was to report on the implementation of the program 
and to evaluate its impact on HCV screening and linkage to care.
METHODS
The Health System and Introduction of a Hepatitis C Virus Screening 
Reminder
UCLA Health consists of approximately 60 outpatient pri-
mary care practices throughout Southern California serving 
approximately 180 000 patients, and it uses an Epic-based elec-
tronic health record (EHR) system (Epic Systems Corporation, 
Verona, WI). We first obtained approval from key stakeholders 
including hospital leadership, primary care group directors, the 
information technology unit, and the clinical laboratory. After 
those administrative approvals, in August 2015 HCV screening 
status was added to the routine health maintenance reminder, 
a clinical decision support (CDS) tool in the EHR, for patients 
born between 1945 and 1965. Within the health maintenance 
reminder, HCV screening was noted as “due” among patients 
with no laboratory evidence of HCV testing (HCV antibody or 
HCV ribonucleic acid [RNA]) in their EHR or if testing was not 
marked as “completed” by the provider. The CDS tool was avail-
able in all charts, but it only appeared on the patient’s dashboard 
if previously activated by the provider.
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Patient Care Coordination
A full-time, nonclinically trained, dedicated HCV care coor-
dinator was introduced in January 2016 in the UCLA Health 
hepatology unit to facilitate follow up and linkage to care for 
HCV positive patients. The UCLA microbiology laboratory 
pulled HCV antibody results from the ADVIA Centaur XP 
System (Siemens Medical Solutions USA, Inc., Malven, PA), 
and, through a secure intrahealth system, sent a daily list of all 
HCV antibody reactive patients to the HCV care coordinator 
by e-mail. The care coordinator used an internal electronic 
message to contact outpatient providers to recommend the fol-
lowing: (1) quantitative HCV RNA testing with reflex to HCV 
genotype testing and (2) noninvasive serum fibrosis testing by 
PROMETHEUS FIBROSpect II (PROMETHEUS Therapeutics 
and Diagnostics, San Diego, CA). The care coordinator did 
not order tests at any time. The provider informed patients of 
test results via telephone, the EHR patient portal, mailed let-
ters, or at the patient’s next visit. After informing the patient, 
the provider contacted the care coordinator to facilitate linkage 
to care through a referral to hepatology or infectious diseases 
for patients with detectable HCV RNA. A flowchart depicting 
the HCV care coordination pathway is presented in Figure 1. 
The HCV care coordinator then telephoned the patient to help 
schedule follow-up visits. Patients indicating they did not wish 
to be linked to care during the initial call were given the care 
coordinator’s direct contact number for future follow up.
Data Collection
Data were abstracted from the EHR for 2 periods: August 1, 
2014 through July 31, 2015 (preimplementation of the HCV 
screening intervention) and August 1, 2015 through July 31, 
2016 (postimplementation). Patients were eligible for inclusion 
if they (1) were born between January 1, 1945 and December 
31, 1965, (2) had a primary care visit between August 1, 2014 
and July 31, 2016, (3) were seen at one of the outpatient clinics 
within UCLA Health, and (4) were tested for HCV during their 
visit. Patients without previous documentation of positive HCV 
antibody or HCV RNA testing within the EHR or a diagnosis in 
their medical record, as determined by electronic chart review, 
were included in the analysis. Data abstraction included age, 
sex, race/ethnicity, as well as HCV testing related data, includ-
ing HCV RNA testing and linkage to care. Linkage to care was 
defined as whether a patient attended an initial appointment 
with an infectious diseases or hepatology specialist within 6 
months of receiving the HCV antibody positive results as doc-
umented in the EHR. The UCLA Institutional Review Board 
approved the study before data collection.
Data Analysis
Summary statistics for demographic and clinical characteristics 
of HCV tested patients overall and by study period (pre- and 
postimplementation) were calculated. The χ2 tests were used to 
compare patient characteristics between the pre- and postimple-
mentation period and between screened and unscreened patients. 
Number of HCV antibody tests, HCV antibody positivity rate 
among those tested, and rate of HCV RNA testing for HCV 
antibody positive patients were assessed for the overall cohort 
and by age, sex, and race/ethnicity. Differences in rates of HCV 
antibody positivity by these demographics were evaluated using 
χ2 tests. The change in the number of HCV antibody tests and 
rates of HCV antibody positivity over the period from preimple-
mentation to postimplementation were assessed using different 
techniques of time series analysis including a Cochran-Armitage 
test for trend, a modified Mann-Kendall test, and a segmented 
regression analysis of interrupted time series [7]. The interrupted 
time series analysis allowed us to examine the intervention effect 
while taking into account time trends as well as any autocorrela-
tions among the observations. The outcomes of interest (HCV 
testing and antibody positivity) were divided into 12  monthly 
data points before implementation of the intervention compared 
with the 12 monthly data points postimplementation. To evalu-
ate the effectiveness of the HCV care coordinator, data were also 
analyzed comparing 2 periods: January 1, 2015–July 31, 2015 
(pre-HCV care coordinator) and January 1, 2016–July 31, 2016 
(post-HCV care coordinator), resulting in 87 antibody positives 
with a record available for review during the pre-HCV care coor-
dinator period and 131 antibody positives during the post-HCV 
care coordinator period. All analyses were conducted using SAS 
version 9.4 (SAS Inc., Cary, NC).
RESULTS
A total of 19 606 patients were tested over the 2-year program 
evaluation period, with a greater proportion of women com-
pared with men (54% vs 46%) and whites representing the single 
largest race/ethnic group (65%), followed by Hispanics/Latinos 
(12%) (Table 1). The number of those newly tested each month 
HCV care
coordinator
receives a daily list
of  HCV Ab
positive patients
HCV care
coordinator
notifies ordering
provider
Ordering provider
notifies patient and
follow up testing is
recommended:
1) quantitative HCV
RNA with reflex to
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2)PROMETHEUS®
FIBROSpect® II
HCV care
coordinator
facilitates
appointment to
Infectious Diseases
or Hepatology
Figure 1. Hepatitis C virus (HCV) linkage to care process. Ab, antibody; RNA, ribonucleic acid.
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increased from 519 patients per month in August 2014 to 1117 
patients per month by July 2016, with a dramatic increase noted 
immediately after program implementation in August 2015 (P 
for trend <.01), with testing frequency remaining stably high 
subsequently (Figure 2). Increases in HCV antibody testing were 
noted across all groups of age, sex, and race/ethnicity, with signif-
icant increases noted among those in the older age groups within 
the cohort (Table 1). A 205% increase in HCV testing was noted 
among those in the oldest age group within the birth cohort 
(ie, 65–71 years) when comparing the numbers tested for HCV 
antibody preprogram implementation to postimplementation. 
Among the racial/ethnic groups, testing increased most substan-
tially among Asian and white racial/ethnic groups (by 121% and 
151%, respectively). The distribution of HCV antibody testing by 
age and sex appeared to closely follow the demographic distri-
bution of primary care visits for baby boomers during the time 
period of interest. Between August 2015 and July 2016, 54.5% of 
primary care visits among those in the birth cohort was among 
women and 45.5% of visits was among men, mirroring the distri-
bution of HCV testing (53.5% women and 46.5% men).
Table 1. HCV Testing Before and After Implementation of an HCV Screening Program Among “Baby Boomers”, UCLA Health System, August 2014–July 
2016
Patient Characteristics
Total (n = 19 606)
August 2014–July 
2015 (n = 5676)a
August 2015–July 
2016 (n = 13 930)a
%Increase in HCV 
Testing P Valuen % n % n %
Age, years <.01
 49–54 5549 28.3 1854 32.7 3695 26.5 99.3
 55–59 5069 25.9 1529 26.9 3540 25.4 131.5
 60–64 4634 23.7 1219 21.5 3415 24.5 180.1
 65–71 4354 22.2 1074 18.9 3280 23.6 205.4
Sex <.01
 Female 10 637 54.2 3192 56.2 7445 53.5 133.2
 Male 8969 45.8 2484 43.8 6485 46.5 161.1
Race/Ethnicity <.01
 Asian 1654 9.6 515 10.0 1139 9.4 121.2
 Black or African American 1172 6.8 419 8.1 753 6.2 79.7
 Hispanic or Latino 2033 11.8 687 13.4 1346 11.1 95.9
 Other 1230 7.1 353 6.9 877 7.3 148.4
 White 11 144 64.6 3169 61.6 7975 66.0 151.7
Abbreviations: HCV, hepatitis C virus; UCLA, University of California, Los Angeles.
aSum may not equal to total due to missing data
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Figure 2. Hepatitis C virus (HCV) antibody testing and percentage positivity before and after implementation of an HCV screening program among baby boomers tested 
through UCLA Health system, August 2014–July 2016. 
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Not surprisingly, as testing increased, HCV antibody positivity 
declined from an average of 4.1% preprogram implementation 
to 1.5% after program implementation (P value for trend <.01) 
(Figure 2). In the year before program implementation, a total 
of 5676 patients were tested for HCV antibody; in the year after 
program implementation, the number tested increased to 13 930 
patients, representing a 145% overall increase in testing. Hepatitis 
C virus antibody positivity varied by age and sex, with a higher 
prevalence among those aged 60–64  years than 49–54  years 
(2.6% vs 1.6%; P value  <  .01) and a higher prevalence among 
males compared with females (3.1% vs 1.5%; P < .01) (Table 2). 
Hepatitis C virus antibody positivity differed by race/ethnicity, 
with the highest prevalence noted among African Americans 
(4.4%) followed by Hispanics (4.1%) in the postimplementation 
period (P < .01). Hepatitis C virus RNA was detected (postimple-
mentation) in 44% of those testing antibody positive. No differ-
ences were noted in HCV RNA detection by age or race/ethnicity, 
although the proportion with detectable HCV RNA was higher 
among men compared with women (50% vs 39%; P = .01).
Although the proportion of HCV antibody positivity 
declined with increased testing, there was a modest increase 
in the absolute number of those testing HCV antibody positive 
during the postimplementation period, most notably among 
60- to 71-year-olds (from 72 positive tests preimplementation 
to 146 positive tests postimplementation, a 103% increase) and 
women (from 66 to 90 positive tests, a 36% increase).
In addition, inclusion of an HCV care coordinator appeared 
instrumental in maintaining high levels of uptake across the 
HCV care continuum. In the period after the addition of the 
HCV care coordinator, the percentage of HCV antibody positive 
patients who received HCV RNA testing increased from 83% 
(pretreatment coordinator) to 95% (P <  .01) (Figure  3). The 
absolute number of those identified with active HCV infection 
(ie, HCV RNA positive) increased from 40 in the preimplemen-
tation to 49 in the postimplementation period (Figure 3). The 
HCV care coordinator was successful in facilitating linkage to 
care for 94% of those identified as HCV RNA positive, a modest 
(nonsignificant) increase from the preimplementation period.
DISCUSSION
Introduction of an HCV screening reminder through an EHR 
CDS tool led to a marked increase in HCV testing among 
the birth cohort, demonstrating the effectiveness of an EHR 
intervention to facilitate uptake of guideline-based recom-
mendations throughout a large health system. The increase in 
testing suggests acceptance of the EHR reminder by providers. 
Acceptance of the reminder was likely facilitated by (1) a sub-
stantial investment in engaging and obtaining the support of 
key stakeholders and health system leadership and (2) minimal 
disruption to physician workflow as HCV screening was added 
to an existing health maintenance reminder. Clinical decision 
support tools have been implemented for other screening and 
prevention recommendations including colorectal cancer 
screening, resulting in higher screening rates over time among 
physicians receiving EHR reminders [8].
The EHR intervention increased HCV screening similarly to 
electronic interventions in other studies [9, 10]. The simplic-
ity and low cost of the EHR intervention and widespread use 
of EHR systems with health maintenance reminders or other 
CDS tools suggests that our EHR intervention may work across 
Table 2. HCV Antibody Positivity Before and After Implementation of an HCV Screening Program Among “Baby Boomers”, UCLA Health System, August 
2014–July 2016
Patient Characteristics
August 2014–July 
2015 (n = 5676)a
August 2015–July 
2016 (n = 13 930)a Total (n = 19 606)
P Value*n % n % n %
Age, years <.01
 49–54 45 2.4 43 1.2 88 1.6
 55–59 63 4.1 53 1.5 116 2.3
 60–64 45 3.7 76 2.2 121 2.6
 65–71 37 3.5 68 2.1 105 2.4
Sex <.01
 Female 66 2.1 90 1.2 156 1.5
 Male 124 5.0 150 2.3 274 3.1
Race/Ethnicity <.01
 Asian 14 2.7 13 1.1 27 1.6
 Black or African American 23 5.5 29 3.9 52 4.4
 Hispanic or Latino 36 5.2 46 3.4 82 4.1
 Other 14 4.0 19 2.2 33 2.7
 White 89 2.8 102 1.3 191 1.7
Abbreviations: HCV, hepatitis C virus; UCLA, University of California, Los Angeles.
aSum may not equal to total due to missing data.
*P value reflects comparisons of HCV antibody positivity for each demographic characteristic.
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different health systems. The impact of a dedicated care coord-
inator on follow up of HCV RNA testing and linkage to care 
is also likely generalizable to other health systems, because the 
function of the coordinator can easily be reproduced and the use 
of a care coordinator might be cost effective. Our study demon-
strated that a clinically trained coordinator is not required to 
link individuals to care effectively and thus nonclinically trained 
professionals may be more affordable for other health systems.
In the BEST-C Study, the cost of different approaches to 
screening was assessed, comparing an electronic best practices 
alert (BPA) as well as medical assistant placement of an HCV 
test order with repeated mailing and patient solicitation [10]. 
The authors found that the BPA intervention had the lowest 
incremental cost per HCV antibody test completed, an approach 
for which, similar to the intervention in the current study, there 
were initial start-up costs for information technology related 
development of the BPA and staff training, but no subsequent 
costs assessed for implementation. It is notable that in BEST-C, 
but not in the approach reported in the current study, personnel 
effort was included in the intervention to initiate an HCV test 
order, but the ongoing cost of the medical assistant (beyond ini-
tial training) was not included in the calculation of the cost of 
the BPA arm. The cost of programming the EHR health main-
tenance reminder is expected to be lower than that of program-
ming a BPA, but the uptake of a health maintenance reminder 
and BPA may differ and influence its cost effectiveness.
Testing increased most notably in select subgroups of older 
age, Asian, and whites, groups that may have previously been 
perceived as lower risk by healthcare providers. As testing 
increased, we saw an expected decrease in HCV antibody posi-
tivity, consistent with a shift to screening based predominantly 
on birth cohort status, whereas preprogram implementation 
screening may have included a combination of risk factor-driven 
testing (enriching the population with HCV infection) with 
some birth cohort-based screening. The previous approach 
would have been more subjected to provider bias or lack of 
awareness regarding risk factors for HCV infection, leading to 
underscreening of the target population [11].
The prevalence of HCV antibody positivity in our cohort (1.5%) 
is lower than that observed in other studies of HCV screening in 
baby boomers, likely due to differences in the sociodemographic 
makeup of the UCLA Health patient population compared with 
other cohorts. Jonas et al [9] described a prevalence of 3.25% 
in a Kaiser Permanente cohort from Maryland, Virginia, and 
the District of Columbia, and Goel et al [12] described a preva-
lence of 3.3% in a New York City university-based primary care 
cohort of persons born between 1945 and 1965; both groups 
showed a greater proportion of black and Hispanic patients. A 
review of HCV seroprevalence in state prisons showed a wide 
range of seroprevalence from 7.5% to 41.2% between states, and 
the prevalence among Hispanic subpopulations also varies by 
Hispanic/Latino background and city, with the highest preva-
lence described in the Bronx and lower prevalence in Chicago, 
Miami, and San Diego [3, 13]. The lower HCV seroprevalence in 
our study may also be explained by differences in the selection 
of the study population, whereby we used both previous labora-
tory testing in the EHR as well as chart review to exclude previ-
ously diagnosed cases of HCV. Other cohorts only excluded cases 
based on laboratory testing available in the EHR, sometimes 
within limited periods, thus potentially including more patients 
with known HCV infection. We did observe a higher prevalence 
of HCV antibody positivity among African Americans and men 
in our cohort, consistent with other studies [9, 14–16].
A lower HCV RNA positivity than expected was also 
observed in our cohort, with a proportion of 44% in the post-
implementation/postcare coordination period compared with 
75.9% and 84% in other studies [9, 12]. Those differences may 
also be explained in part by differences in the racial/ethnic 
makeup of the cohorts, as black or African American individ-
uals have a lower rate of spontaneous HCV clearance compared 
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with whites, which is partly explained by host genetic differences 
[17], and our cohort had a smaller proportion of black patients.
Our findings support the use of CDS and dedicated HCV care 
coordination to successfully scale-up HCV screening and linkage 
to care within a health system. Barriers to successful linkage were 
minimal in the postimplementation period, as noted in Figure 3. 
The only barrier to linkage identified was patients stating that 
they were not ready for an appointment with an HCV specialist 
at the time they received a call from the HCV care coordinator.
There were other external factors to consider as possible lim-
itations to the interpretation of our findings, such as ongoing 
advertisements in the media and other news reports as well 
as changes in legislation, litigation, and policy related to HCV 
that we were unable to control for in this study. Another fac-
tor influencing higher screening might have been changes in 
the number of clinical sites served over the observation period. 
Those factors may have influenced higher screening and link-
age to care rates as awareness about HCV and available treat-
ments in the general population increased. Although those 
factors might have influenced higher screening and linkage to 
care rates, the sharp increase in screening and lack of contin-
ued increase over time suggest that the impact of those factors 
was minimal. A further limitation is that the CDS tool required 
activation as well as purposeful review by providers, and thus 
not all providers would have been reminded of the screening 
recommendation. Follow-up HCV RNA testing to assess for 
active HCV infection also required a provider to order HCV 
RNA testing and that the patient return for follow-up specimen 
collection. To address those barriers to screening and con-
firmation of HCV infection, the allowance of a dedicated staff 
member to activate the CDS tool on all patients and the use of 
reflex HCV RNA testing for positive HCV antibody tests could 
further improve outcomes [9]. Implementation of the screening 
program required (1) health system leadership and (2) partici-
pation from various departments that might limit feasibility in 
a more resource-constrained health delivery setting.
An additional limitation of the study was that the preimple-
mentation data were collected retrospectively. Approximately 
20% of the anti-HCV positive patients in that period had miss-
ing HCV RNA testing data. It is possible that some patients in 
the preimplementation period had screening or follow up out-
side of UCLA that was not captured.
CONCLUSIONS
Implementation of national guidelines for HCV screening at the 
health system level through a multipronged approach, includ-
ing decision support tools within the EHR and dedicated care 
coordination, although requiring substantial initiative, has the 
potential to rapidly scale up HCV screening and reduce gaps at 
every step in the HCV care cascade. With the current availabil-
ity of highly effective and well tolerated curative HCV therapy, 
such an investment is likely to have an impact on decreasing the 
HCV-related disease burden, improving patient outcomes, and 
reducing future healthcare costs.
Acknowledgments
We thank Dr. Omai Garner and the UCLA Microbiology Laboratory staff 
for help and support with data retrieval. We also thank Arash Shamsian 
from UCLA Information Services & Solutions.
Financial support. The National Center for Advancing Translational 
Sciences at the National Institutes of Health with the University of 
California, Los Angeles (UCLA) Clinical and Translational Science Institute 
(UL1TR001881) provided funding for data extraction and preparation. 
UCLA Health provided funding for the modification of the EHR. Gilead 
Sciences, Incorporated as Frontlines of Communities in the United States 
(FOCUS) program partners (20161077) provided funding for a bachelor 
level coordinator as well as part of the time and effort of the principal inves-
tigator and data analyst.
Potential conflicts of interest. K. W. C. reports other funding from the Gilead 
Focus Award, during the conduct of the study; and grants from Merck Sharp & 
Dohme, outside the submitted work. S. S. is a part of the advisory board, a con-
sultant, and on the speaker bureau for AbbVie, BMS, Gilead, Janssen, and Merck. 
All authors have submitted the ICMJE Form for Disclosure of Potential 
Conflicts of Interest. Conflicts that the editors consider relevant to the con-
tent of the manuscript have been disclosed.
References
1. Moyer VA; U.S. Preventive Services Task Force. Screening for hepatitis C virus 
infection in adults: U.S. Preventive Services Task Force recommendation state-
ment. Ann Intern Med 2013; 159:349–57.
2. Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification 
of chronic hepatitis C virus infection among persons born during 1945–1965. 
MMWR Recomm Rep 2012; 61:1–32.
3. Edlin BR, Eckhardt BJ, Shu MA, et al. Toward a more accurate estimate of the 
prevalence of hepatitis C in the United States. Hepatology 2015; 62:1353–63.
4. Linas BP, Barter DM, Leff JA, et al. The hepatitis C cascade of care: identifying 
priorities to improve clinical outcomes. PLoS One 2014; 9:e97317.
5. Yehia BR, Schranz AJ, Umscheid CA, Lo Re V 3rd. The treatment cascade for 
chronic hepatitis C virus infection in the United States: a systematic review and 
meta-analysis. PLoS One 2014; 9:e101554.
6. Ward JW. The epidemiology of chronic hepatitis C and one-time hepatitis C virus 
testing of persons born during 1945 to 1965 in the United States. Clin Liver Dis 
2013; 17:1–11.
7. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression anal-
ysis of interrupted time series studies in medication use research. J Clin Pharm 
Ther 2002; 27:299–309.
8. Sequist TD, Zaslavsky AM, Marshall R, et al. Patient and physician reminders to 
promote colorectal cancer screening: a randomized controlled trial. Arch Intern 
Med 2009; 169:364–71.
9. Jonas MC, Rodriguez CV, Redd J, et al. Streamlining screening to treatment: the 
hepatitis C cascade of care at Kaiser Permanente Mid-Atlantic States. Clin Infect 
Dis 2016; 62:1290–6.
10. Brady JE, Liffmann DK, Yartel A, et al. Uptake of hepatitis C screening, character-
istics of patients tested, and intervention costs in the BEST-C study. Hepatology 
2017; 65:44–53.
11. Ferrante JM, Winston DG, Chen PH, de la Torre AN. Family physicians’ knowledge 
and screening of chronic hepatitis and liver cancer. Fam Med 2008; 40:345–51.
12. Goel A, Sanchez J, Paulino L, et al. A systematic model improves hepatitis C virus 
birth cohort screening in hospital-based primary care. J Viral Hepat 2017; 24:477–85.
13. Kuniholm MH, Jung M, Everhart JE, et al. Prevalence of hepatitis C virus infec-
tion in US Hispanic/Latino adults: results from the NHANES 2007–2010 and 
HCHS/SOL studies. J Infect Dis 2014; 209:1585–90.
14. Spradling PR, Rupp L, Moorman AC, et  al. Hepatitis B and C virus infection 
among 1.2 million persons with access to care: factors associated with testing and 
infection prevalence. Clin Infect Dis 2012; 55:1047–55.
15. Cartwright EJ, Rentsch C, Rimland D. Hepatitis C virus screening practices and 
seropositivity among US veterans born during 1945–1965. BMC Res Notes 2014; 
7:449.
16. Coyle C, Viner K, Hughes E, et  al. Identification and linkage to care of HCV-
infected persons in five health centers–Philadelphia, Pennsylvania, 2012–2014. 
MMWR Morb Mortal Wkly Rep 2015; 64:459–63.
17. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontane-
ous clearance of hepatitis C virus. Nature 2009; 461:798–801.
